155 related articles for article (PubMed ID: 14985870)
1. Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer.
Soerdjbalie-Maikoe V; Pelger RC; Lycklama à Nijeholt GA; Arndt JW; Zwinderman AH; Bril H; Papapoulos SE; Hamdy NA
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):958-63. PubMed ID: 14985870
[TBL] [Abstract][Full Text] [Related]
2. Premature conclusions may harm good ideas.
Staudenherz A; Sinzinger H
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):625-6; author reply 627. PubMed ID: 15723225
[No Abstract] [Full Text] [Related]
3. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
Soerdjbalie-Maikoe V; Pelger RC; Lycklama à Nijeholt GA; Arndt JW; Zwinderman AH; Papapoulos SE; Hamdy NA
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):494-8. PubMed ID: 11914887
[TBL] [Abstract][Full Text] [Related]
4. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
5. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
6. Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis?
Chiewvit P; Danchaivijitr N; Sirivitmaitrie K; Chiewvit S; Thephamongkhol K
J Med Assoc Thai; 2009 Jun; 92(6):818-29. PubMed ID: 19530588
[TBL] [Abstract][Full Text] [Related]
7. Preserved value of bone scintigraphy for the detection of skeletal metastases in prostate cancer patients with low prostate-specific antigen levels: effect of hormonal therapy and poor histologic differentiation.
Caglar M; Tuncel M
Clin Nucl Med; 2002 Jul; 27(7):532-3. PubMed ID: 12072787
[No Abstract] [Full Text] [Related]
8. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy.
Rigaud J; Tiguert R; Le Normand L; Karam G; Glemain P; Buzelin JM; Bouchot O
J Urol; 2002 Oct; 168(4 Pt 1):1423-6. PubMed ID: 12352409
[TBL] [Abstract][Full Text] [Related]
9. Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer.
Kalkner KM; Acosta S; Thorsson O; Frederiksen H; Nilsson A; Gustavsson B; Elingsbo M; Stridsberg M; Abrahamsson PA
Prostate Cancer Prostatic Dis; 2006; 9(1):92-8. PubMed ID: 16231013
[TBL] [Abstract][Full Text] [Related]
10. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results.
Roudier MP; Vesselle H; True LD; Higano CS; Ott SM; King SH; Vessella RL
Clin Exp Metastasis; 2003; 20(2):171-80. PubMed ID: 12705638
[TBL] [Abstract][Full Text] [Related]
11. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
14. Predicting survival for surgery of metastatic spinal cord compression in prostate cancer: a new score.
Crnalic S; Löfvenberg R; Bergh A; Widmark A; Hildingsson C
Spine (Phila Pa 1976); 2012 Dec; 37(26):2168-76. PubMed ID: 22648028
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
Inoue T; Segawa T; Kamba T; Yoshimura K; Nakamura E; Nishiyama H; Ito N; Kamoto T; Habuchi T; Ogawa O
Urology; 2009 May; 73(5):1104-9. PubMed ID: 19394511
[TBL] [Abstract][Full Text] [Related]
17. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
18. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
[TBL] [Abstract][Full Text] [Related]
19. Adenocarcinoma of the prostate and metastatic medullary compression. A retrospective study of 22 patients.
Honnens de Lichtenberg M; Kvist E; Hjortberg P; Karle A
Scand J Urol Nephrol; 1992; 26(1):25-8. PubMed ID: 1631503
[TBL] [Abstract][Full Text] [Related]
20. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
